322 related articles for article (PubMed ID: 23075176)
1. Relapse risk after discontinuation of risperidone in Alzheimer's disease.
Devanand DP; Mintzer J; Schultz SK; Andrews HF; Sultzer DL; de la Pena D; Gupta S; Colon S; Schimming C; Pelton GH; Levin B
N Engl J Med; 2012 Oct; 367(16):1497-507. PubMed ID: 23075176
[TBL] [Abstract][Full Text] [Related]
2. Prediction of Relapse After Discontinuation of Antipsychotic Treatment in Alzheimer's Disease: The Role of Hallucinations.
Patel AN; Lee S; Andrews HF; Pelton GH; Schultz SK; Sultzer DL; Mintzer J; de la Pena D; Gupta S; Colon S; Schimming C; Levin B; Devanand DP
Am J Psychiatry; 2017 Apr; 174(4):362-369. PubMed ID: 27855483
[TBL] [Abstract][Full Text] [Related]
3. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia.
Brodaty H; Ames D; Snowdon J; Woodward M; Kirwan J; Clarnette R; Lee E; Lyons B; Grossman F
J Clin Psychiatry; 2003 Feb; 64(2):134-43. PubMed ID: 12633121
[TBL] [Abstract][Full Text] [Related]
4. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
De Deyn PP; Katz IR; Brodaty H; Lyons B; Greenspan A; Burns A
Clin Neurol Neurosurg; 2005 Oct; 107(6):497-508. PubMed ID: 15922506
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.
Schneider LS; Tariot PN; Dagerman KS; Davis SM; Hsiao JK; Ismail MS; Lebowitz BD; Lyketsos CG; Ryan JM; Stroup TS; Sultzer DL; Weintraub D; Lieberman JA;
N Engl J Med; 2006 Oct; 355(15):1525-38. PubMed ID: 17035647
[TBL] [Abstract][Full Text] [Related]
6. The antipsychotic discontinuation in Alzheimer disease trial: clinical rationale and study design.
Devanand DP; Mintzer J; Schultz S; Sultzer D; de la Pena D; Gupta S; Colon S; Schimming C; Pelton GH; Andrews H; Levin B
Am J Geriatr Psychiatry; 2012 Apr; 20(4):362-73. PubMed ID: 21407047
[TBL] [Abstract][Full Text] [Related]
7. A 6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer's disease.
Devanand DP; Pelton GH; Cunqueiro K; Sackeim HA; Marder K
Int J Geriatr Psychiatry; 2011 Sep; 26(9):937-43. PubMed ID: 21845596
[TBL] [Abstract][Full Text] [Related]
8. Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial.
Sultzer DL; Davis SM; Tariot PN; Dagerman KS; Lebowitz BD; Lyketsos CG; Rosenheck RA; Hsiao JK; Lieberman JA; Schneider LS;
Am J Psychiatry; 2008 Jul; 165(7):844-54. PubMed ID: 18519523
[TBL] [Abstract][Full Text] [Related]
9. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease.
Ballard C; Waite J
Cochrane Database Syst Rev; 2006 Jan; (1):CD003476. PubMed ID: 16437455
[TBL] [Abstract][Full Text] [Related]
10. Risperidone for psychosis of Alzheimer's disease and mixed dementia: results of a double-blind, placebo-controlled trial.
Brodaty H; Ames D; Snowdon J; Woodward M; Kirwan J; Clarnette R; Lee E; Greenspan A
Int J Geriatr Psychiatry; 2005 Dec; 20(12):1153-7. PubMed ID: 16315159
[TBL] [Abstract][Full Text] [Related]
11. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia.
Declercq T; Petrovic M; Azermai M; Vander Stichele R; De Sutter AI; van Driel ML; Christiaens T
Cochrane Database Syst Rev; 2013 Mar; (3):CD007726. PubMed ID: 23543555
[TBL] [Abstract][Full Text] [Related]
12. Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia.
Deberdt WG; Dysken MW; Rappaport SA; Feldman PD; Young CA; Hay DP; Lehman DL; Dossenbach M; Degenhardt EK; Breier A
Am J Geriatr Psychiatry; 2005 Aug; 13(8):722-30. PubMed ID: 16085789
[TBL] [Abstract][Full Text] [Related]
13. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group.
Katz IR; Jeste DV; Mintzer JE; Clyde C; Napolitano J; Brecher M
J Clin Psychiatry; 1999 Feb; 60(2):107-15. PubMed ID: 10084637
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials.
Katz I; de Deyn PP; Mintzer J; Greenspan A; Zhu Y; Brodaty H
Int J Geriatr Psychiatry; 2007 May; 22(5):475-84. PubMed ID: 17471598
[TBL] [Abstract][Full Text] [Related]
15. Treating behavioral and psychological symptoms in patients with psychosis of Alzheimer's disease using risperidone.
Rabinowitz J; Katz I; De Deyn PP; Greenspan A; Brodaty H
Int Psychogeriatr; 2007 Apr; 19(2):227-40. PubMed ID: 16879763
[TBL] [Abstract][Full Text] [Related]
16. Discontinuation of risperidone in Alzheimer's disease.
Ling SM; Bonner AF; McMullen TL
N Engl J Med; 2013 Jan; 368(2):187. PubMed ID: 23301740
[No Abstract] [Full Text] [Related]
17. Discontinuation of risperidone in Alzheimer's disease.
Power GA
N Engl J Med; 2013 Jan; 368(2):186-7. PubMed ID: 23301739
[No Abstract] [Full Text] [Related]
18. Discontinuation of risperidone in Alzheimer's disease.
Gnjidic D; Hilmer SN
N Engl J Med; 2013 Jan; 368(2):186. PubMed ID: 23301738
[No Abstract] [Full Text] [Related]
19. Discontinuation of risperidone in Alzheimer's disease.
Devanand DP; Schultz SK; Sultzer DL
N Engl J Med; 2013 Jan; 368(2):187-8. PubMed ID: 23301737
[No Abstract] [Full Text] [Related]
20. Risperidone in the treatment of psychosis of Alzheimer disease: results from a prospective clinical trial.
Mintzer J; Greenspan A; Caers I; Van Hove I; Kushner S; Weiner M; Gharabawi G; Schneider LS
Am J Geriatr Psychiatry; 2006 Mar; 14(3):280-91. PubMed ID: 16505133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
